Business context and reporting period
The supplied filing is Bioblast Pharma Ltd.’s Form 20-F for the fiscal year ended December 31, 2016, filed February 24, 2017—not a filing identified as Enlivex Ltd. The company was a clinical-stage biotechnology business developing intravenous trehalose (Trehalose IV) for rare diseases, principally OPMD and SCA3. This is an annual report; it also provides unaudited quarterly results for 2016.
Financial and operating performance
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $8.881 million | $7.694 million |
| Pre-commercialization expense | $1.085 million | $0.829 million |
| General and administrative expense | $5.900 million | $6.953 million |
| Total operating expenses / operating loss | $15.866 million | $15.476 million |
| Net loss | $16.022 million | $15.365 million |
| Net loss per share, basic and diluted | $1.01 | $1.08 |
| Net cash used in operating activities | $15.486 million | $13.249 million |
| Cash, cash equivalents and short-term deposits at year-end | $9.878 million | $19.332 million |
| Total assets / total liabilities | $10.630 million / $1.931 million | $20.516 million / $2.584 million |
There was no commercial revenue, so revenue-based margins are not meaningful. The company reported no outstanding borrowings. FY 2016 financing cash flow was $6.089 million, principally net proceeds from a March registered direct share and warrant offering; investing cash inflow of $8.982 million mainly reflected maturities or withdrawals of short-term deposits.
Changes versus the prior comparable period
Operating expenses rose 2.5% overall: R&D increased 15%, reflecting compensation and preparation for the planned OPMD Phase 2b trial; pre-commercialization costs increased 31%; and G&A fell 15% following U.S. workforce reductions and office closures. Net loss increased by $0.657 million, while loss per share improved from $1.08 to $1.01 as the weighted-average share count increased. Operating cash use rose $2.237 million. Cash and short-term deposits declined by $9.454 million, notwithstanding the 2016 equity financing.
The company issued 2,161,290 shares in March 2016 at $3.10 per share and also issued warrants for 1,080,645 shares at a $4.50 exercise price. Year-end shares outstanding were 16,391,770, versus 14,230,480 a year earlier.
Outlook, risks and notable items
- Management expected available cash to fund operations only through at least the end of Q2 2017. Additional funding was required to cover the planned OPMD Phase 2b study and ongoing operations; the independent auditor’s report and the filing state that substantial doubt exists about the company’s ability to continue as a going concern.
- Subject to regulatory approval and financing, management planned a 24-week, double-blind, placebo-controlled Phase 2b OPMD study enrolling 48 patients, and intended to pursue early clinical testing in other indications during 2017. These were plans, not reported outcomes.
- Reported Phase 2a results were preliminary and not proof of efficacy. In the 25-patient open-label OPMD study, the company reported safety/tolerability and exploratory efficacy signals; in the 14-patient SCA3 study, patients were reported stable on the SARA scale. The filing cautions that early-stage findings may not be replicated.
- Clinical and development risks include trial delays or failure, limited rare-disease patient pools, safety or regulatory setbacks, and uncertain market size, pricing, reimbursement and commercialization. The company relied on third parties for manufacturing and clinical work, including a single supplier of raw materials and a single manufacturer for Trehalose IV.
- In June 2016, the company downsized and terminated U.S. employees; it reported $1.907 million in termination-related payments. It also discontinued other product activities and terminated licenses for non-trehalose platforms during 2016. The common stock’s reported 2016 trading range was $0.92–$7.95.
Key facts investors should verify
- Confirm the issuer identity: the request names Enlivex Ltd., but the supplied filing is for Bioblast Pharma Ltd.
- Verify current liquidity, subsequent financing, and whether the stated Q2 2017 cash runway and going-concern uncertainty were resolved.
- Check whether the planned Phase 2b OPMD trial and additional-indication studies began, their enrollment and results, and any later regulatory updates.
- Review audited financial statements and notes for cash balances, liabilities, share and warrant dilution, and termination-related costs; the filing’s financial statements are prepared under U.S. GAAP.
- Assess the assumptions behind the company’s clinical signals, patient-market estimates, manufacturing continuity, and ability to raise capital.